DELFI Diagnostics Welcomes Cindy Soriano as Chief Financial Officer
In a significant move for DELFI Diagnostics, the company has appointed Cindy Soriano as its new Chief Financial Officer. This strategic decision comes at a crucial time as DELFI prepares to hit pivotal clinical and regulatory milestones in its development of innovative blood-based tests for cancer detection.
Expertise in Finance and Leadership
Cindy Soriano brings with her two decades of experience in finance leadership, making her an asset to DELFI as they navigate the complexities of the healthcare landscape. Previously, she served as the Vice President of Finance and Investor Relations at DELFI, where she played a major role in establishing the company's financial structure during critical fundraising moments. Her leadership and vision are expected to propel DELFI forward as they strive to achieve their ambitious goals.
Significance of the Appointment
CEO Susan Tousi expressed confidence in Soriano’s capabilities, stating, “Cindy's promotion comes at a pivotal moment for DELFI as we prepare to achieve key clinical and regulatory milestones.” With a solid foundation built under her financial guidance, DELFI is now better equipped to fulfill its mission and enhance long-term value for shareholders and patients alike.
A Background of Achievements
Before her tenure at DELFI, Cindy held several significant finance roles within the life sciences sector. Notably, she was instrumental in leading the finance organization at Zogenix during its acquisition by UCB, showcasing her ability to handle complex financial landscapes during vital transitions. Additionally, at BioMarin Pharmaceuticals, she held leadership positions, focusing on operational and strategic planning across a wide range of projects.
Participation in the J.P. Morgan Healthcare Conference
In conjunction with this leadership change, DELFI Diagnostics is gearing up for the 44th Annual J.P. Morgan Healthcare Conference. Susan Tousi, the CEO, is scheduled to present key updates about the company’s progress and strategic focus. This presentation will take place on January 15, 2026, and is anticipated to outline DELFI's direction moving forward.
About the J.P. Morgan Healthcare Conference
The J.P. Morgan Healthcare Conference is a prestigious annual event that gathers industry leaders to share insights and drive discussions around healthcare innovations. Participations like DELFI's highlight their commitment to transparency and stakeholder engagement, providing a valuable opportunity for investors to learn about the company's advancements in cancer detection technology.
About DELFI Diagnostics
DELFI Diagnostics stands at the forefront of developing the next generation of blood-based tests aimed at improving early cancer detection. The company’s innovative tests tackle significant population health issues, particularly within historically underserved communities, and aim to enhance survival rates worldwide. The flagship product, FirstLook Lung, is designed for individuals who meet criteria for lung cancer screening. This test provides an easy and less invasive method of cancer detection through a simple blood draw, which can seamlessly integrate into routine health check-ups.
Utilizing fragmentomics, DELFI’s approach focuses on the unique characteristics of cell-free DNA (cfDNA) fragments released by cancerous cells upon death. By analyzing these patterns with advanced machine-learning algorithms applied to whole-genome sequencing data, DELFI aims to accurately identify potential cancers, including early-stage diseases, boasting an impressive negative predictive value of 99.8%. It’s important to note that while promising, this test remains under review and has yet to receive FDA clearance.
To learn more about their revolutionary technology and ongoing efforts, DELFI invites you to visit DELFIDiagnostics.com.
Frequently Asked Questions
What is the role of Cindy Soriano at DELFI Diagnostics?
Cindy Soriano serves as the Chief Financial Officer, bringing extensive experience and expertise to guide the company through critical financial decisions.
When is the J.P. Morgan Healthcare Conference?
The J.P. Morgan Healthcare Conference is scheduled for January 15, 2026, where DELFI CEO Susan Tousi will present.
What is DELFI Diagnostics known for?
DELFI Diagnostics is recognized for developing advanced blood-based tests for cancer detection, aimed at improving early diagnosis.
What is FirstLook Lung?
FirstLook Lung is DELFI's flagship product designed for lung cancer screening through a simple blood draw, offering a new method for early detection.
What technology does DELFI utilize in its tests?
DELFI uses fragmentomics and machine-learning algorithms to analyze cfDNA patterns associated with cancer, enhancing the accuracy of their tests.
